Tiragolumab
- Generic Name
- Tiragolumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1918185-84-8
- Unique Ingredient Identifier
- 6XG22YQM2Z
- Background
Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT06754501
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
- Conditions
- Microsatellite Stable Metastatic Colorectal CancerMetastatic Colorectal CancerColorectal Cancer
- Interventions
- Biological: TiragolumabBiological: AtezolizumabRadiation: Stereotactic Body Radiation Therapy (SBRT)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT06603818
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype
- Interventions
- Biological: AtezolizumabProcedure: Biospecimen CollectionProcedure: Magnetic Resonance ImagingProcedure: Surgical ProcedureBiological: Tiragolumab
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT06328036
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT05862285
- Locations
- 🇧🇪
GHdC Site Notre Dame, Charleroi, Belgium
🇫🇷Institut de Cancérologie de Bourgogne, Dijon, France
🇫🇷Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque, Montpellier, France
An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma
- Conditions
- Gastric and Gastroesophageal Junction Carcinoma
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT05251948
- Locations
- 🇨🇳
the First Hospital of Jilin University, Changchun, China
🇨🇳First Affiliated Hospital of Gannan Medical University, Ganzhou, China
🇨🇳Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
- Conditions
- Urothelial CarcinomaBladder Cancer
- Interventions
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 272
- Registration Number
- NCT03869190
- Locations
- 🇫🇷
Centre Francois Baclesse, Caen, France
🇬🇷Attiko Hospital University of Athens, Athens, Greece
🇬🇷Athens Medical Center, Athens, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.